Vesugen

Vesugen (KED, Lys-Glu-Asp)

Full Research Introduction & Administration Guide IMPORTANT DISCLAIMER: For laboratory research use only. Not approved for human injection, clinical treatment or consumption. All dosing information is summarized from published preclinical literature purely for experimental reference.

1. Basic Overview

Vesugen (Code T-38, Sequence Lys-Glu-Asp / KED) is a synthetic short tripeptide bioregulator developed by the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson peptide series). It is engineered to regulate vascular endothelial cell function.

• CAS Number: 204271-66-9
• Molecular Formula: C₁₅H₂₆N₄O₈
• Molecular Weight: 390.39 Da
• Form: Lyophilized white crystalline powder
• Half-life: ~30 minutes
• Core Feature: Ultrashort peptide capable of penetrating cell nuclei to modulate gene expression epigenetically; primary target: vascular endothelial tissue.

2. Mechanism of Action

1. Endothelial Cell Protection Interacts with the promoter of the MKI67 (Ki-67) gene to regulate endothelial cell proliferation, reduce endothelial apoptosis, and maintain the integrity of blood vessel walls. Normalizes endothelin-1 levels to ease vasoconstriction stress.
2. Anti-Atherosclerotic Activity Upregulates SIRT1 expression; improves intercellular gap junction proteins (Cx37, Cx43). Supports lipid metabolism balance and reduces pathological vascular remodeling.
3. Microcirculation Improvement Promotes balanced angiogenesis, enhances peripheral blood flow, and alleviates disorders of microvascular circulation.
4. Neuroprotective Effects Modulates neuronal markers (Nestin, GAP43). In preclinical aging & Alzheimer’s models, it supports neuroplasticity and protects cerebrovascular tissue.
5. Geroprotective Properties Reduces age-related degenerative changes in arteries; often researched in combination with other organ-specific bioregulator peptides (Cardiogen, Cortagen).

3. Main Research Applications

• Vascular endothelial aging & endothelial dysfunction research
• Atherosclerosis, peripheral circulatory impairment experimental models
• Hypertension, hyperlipidemia & cardiovascular aging studies
• Cerebrovascular health and neurodegeneration preclinical research
• Microcirculation disturbance & tissue perfusion experiments
• Combined bioregulator therapy research (Vesugen + Cardiogen)
• Peptide epigenetic regulation & short peptide bioregulator pharmacology

4. Reconstitution Instructions (Lyophilized Vial)

Common specification: 15mg / 20mg per vial

1. Allow vial to reach room temperature; disinfect rubber stopper with alcohol.
2. Slowly inject Bacteriostatic Water along the inner glass wall. Avoid direct impact onto lyophilized powder.

3. Gently rotate the vial to dissolve powder. DO NOT shake violently to prevent peptide degradation. Qualified solution is clear and colourless.
4. Storage Requirements

• Unreconstituted lyophilized powder: Hermetically sealed, stored at -20°C, protected from light. Stable for up to 24 months.
• Reconstituted peptide solution: Refrigerate 2°C ~ 8°C, stable within 28 days. Do not freeze reconstituted liquid.

5. Research Administration Protocols

Primary Route: Subcutaneous Injection

Reference Experimental Dosage (Preclinical Research Reference)

• Low tolerance dose: 100–150 mcg once daily
• Standard experimental dose: 200–300 mcg once daily
• Higher experimental dose: Up to 1 mg once daily (limited long-term safety data)
• Injection site: Lower abdomen, anterior thigh; rotate injection positions regularly.

Reference Experimental Cycle (Khavinson pulsed bioregulator protocol)

Continuous administration for 10–14 consecutive days as one course. Minimum 6–8 weeks washout interval before starting a new experimental course.

6. Precautions & Observed Adverse Reactions

1. Pure laboratory research compound. Not authorized for human therapeutic use.
2. Strict aseptic technique required during reconstitution to prevent microbial contamination.
3. Discard solution immediately if turbidity, precipitation or discoloration appears.
4. Minimal reported adverse effects in standard research dosages; occasional mild transient redness at injection site.
5. Limited independent long-term high-dose safety data. Avoid uninterrupted administration beyond 14 days without washout.
6. For vascular research, Vesugen is frequently combined with Cardiogen for synergistic cardiovascular study models.

Short Version (For Product Page / Customer Direct Message)

Vesugen (KED, Lys-Glu-Asp)

Vesugen is a synthetic tripeptide bioregulator from the Khavinson peptide series. It targets vascular endothelial cells via epigenetic gene modulation, supporting blood vessel wall integrity, improving microcirculation and exerting vasoprotective and neuroprotective effects. Widely used in laboratory research on vascular aging, atherosclerosis, circulatory disorders and cerebrovascular health.

Reconstitution

Mix lyophilized powder with bacteriostatic water. Rotate gently; avoid violent shaking. Reconstituted solution must be refrigerated and used within 28 days.

Reference Subcutaneous Research Dosage

100–300 mcg once daily, administered in 10–14 day pulsed experimental courses.